<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39274971</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1420-3049</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>17</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>30</Day></PubDate></JournalIssue><Title>Molecules (Basel, Switzerland)</Title><ISOAbbreviation>Molecules</ISOAbbreviation></Journal><ArticleTitle>Application of PLGA-PEG-PLGA Nanoparticles to Percutaneous Immunotherapy for Food Allergy.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">4123</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/molecules29174123</ELocationID><Abstract><AbstractText>Compared with oral or injection administration, percutaneous immunotherapy presents a promising treatment modality for food allergies, providing low invasiveness and safety. This study investigated the efficacy of percutaneous immunotherapy using hen egg lysozyme (HEL)-loaded PLGA-PEG-PLGA nanoparticles (NPs), as an antigen model protein derived from egg white, compared with that of HEL-loaded chitosan hydroxypropyltrimonium chloride (CS)-modified PLGA NPs used in previous research. The intradermal retention of HEL in excised mouse skin was measured using Franz cells, which revealed a 2.1-fold higher retention with PLGA-PEG-PLGA NPs than that with CS-modified PLGA NPs. Observation of skin penetration pathways using fluorescein-4-isothiocyanate (FITC)-labeled HEL demonstrated successful delivery of HEL deep into the hair follicles with PLGA-PEG-PLGA NPs. These findings suggest that after NPs delivery into the skin, PEG prevents protein adhesion and NPs aggregation, facilitating stable delivery deep into the skin. Subsequently, in vivo percutaneous administration experiments in mice, with concurrent iontophoresis, demonstrated a significant increase in serum IgG1 antibody production with PLGA-PEG-PLGA NPs compared with that with CS-PLGA NPs after eight weeks of administration. Furthermore, serum IgE production in each NP administration group significantly decreased compared with that by subcutaneous administration of HEL solution. These results suggest that the combination of PLGA-PEG-PLGA NPs and iontophoresis is an effective percutaneous immunotherapy for food allergies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sakurai</LastName><ForeName>Ryuse</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641, Yamazaki, Noda 278-8510, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwata</LastName><ForeName>Hanae</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641, Yamazaki, Noda 278-8510, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gotoh</LastName><ForeName>Masaki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Modality Research Group, BioPharma Research Institute, Kaneka Corporation Inc., 1-8 Miyamae-cho, Takasago-cho, Takasago-shi 676-8688, Hyogo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogino</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Modality Research Group, BioPharma Research Institute, Kaneka Corporation Inc., 1-8 Miyamae-cho, Takasago-cho, Takasago-shi 676-8688, Hyogo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takeuchi</LastName><ForeName>Issei</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-0611-7387</Identifier><AffiliationInfo><Affiliation>Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641, Yamazaki, Noda 278-8510, Chiba, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Pharmaceutical Sciences, Josai International University, 1 Gumyo, Togane 283-8555, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makino</LastName><ForeName>Kimiko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641, Yamazaki, Noda 278-8510, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Itoh</LastName><ForeName>Fumio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641, Yamazaki, Noda 278-8510, Chiba, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gastroenterology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku 216-8511, Kawasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saitoh</LastName><ForeName>Akiyoshi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641, Yamazaki, Noda 278-8510, Chiba, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Molecules</MedlineTA><NlmUniqueID>100964009</NlmUniqueID><ISSNLinking>1420-3049</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>3WJQ0SDW1A</RegistryNumber><NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.17</RegistryNumber><NameOfSubstance UI="D009113">Muramidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.-</RegistryNumber><NameOfSubstance UI="C421864">hen egg lysozyme</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000589473">polyethylene glycol-poly(lactide-co-glycolide)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>34346-01-5</RegistryNumber><NameOfSubstance UI="D011098">Polyglactin 910</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011091">Polyesters</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011092" MajorTopicYN="Y">Polyethylene Glycols</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005512" MajorTopicYN="Y">Food Hypersensitivity</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009113" MajorTopicYN="N">Muramidase</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012867" MajorTopicYN="N">Skin</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000279" MajorTopicYN="N">Administration, Cutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011098" MajorTopicYN="N">Polyglactin 910</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004337" MajorTopicYN="N">Drug Carriers</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011091" MajorTopicYN="N">Polyesters</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PLGA</Keyword><Keyword MajorTopicYN="N">PLGA-PEG-PLGA</Keyword><Keyword MajorTopicYN="N">allergen immunotherapy (AIT)</Keyword><Keyword MajorTopicYN="N">epicutaneous immunotherapy (EPIT)</Keyword><Keyword MajorTopicYN="N">food allergy</Keyword><Keyword MajorTopicYN="N">iontophoresis</Keyword><Keyword MajorTopicYN="N">nanoparticles</Keyword><Keyword MajorTopicYN="N">percutaneous absorption</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>10</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>10</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>1</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39274971</ArticleId><ArticleId IdType="pmc">PMC11397245</ArticleId><ArticleId IdType="doi">10.3390/molecules29174123</ArticleId><ArticleId IdType="pii">molecules29174123</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Loh W., Tang M.L.K. The epidemiology of food allergy in the global context. Int. J. Environ. Res. Public Health. 2018;15:2043. doi: 10.3390/ijerph15092043.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph15092043</ArticleId><ArticleId IdType="pmc">PMC6163515</ArticleId><ArticleId IdType="pubmed">30231558</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardona V., Ansotegui I.J., Ebisawa M., El-Gamal Y., Rivas M.F., Fineman S., Geller M., Gonzalez-Estrada A., Greenberger P.A., Borges M.S., et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ. J. 2020;13:100472. doi: 10.1016/j.waojou.2020.100472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.waojou.2020.100472</ArticleId><ArticleId IdType="pmc">PMC7607509</ArticleId><ArticleId IdType="pubmed">33204386</ArticleId></ArticleIdList></Reference><Reference><Citation>Longo G., Berti I., Burks A.W., Krauss B., Barbi E. IgE-mediated food allergy in children. Lancet. 2013;382:1656–1664. doi: 10.1016/S0140-6736(13)60309-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)60309-8</ArticleId><ArticleId IdType="pubmed">23845860</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhawt M. Food allergy quality of life and living with food allergy. Curr. Opin. Allergy Clin. Immunol. 2016;16:284–290. doi: 10.1097/ACI.0000000000000271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ACI.0000000000000271</ArticleId><ArticleId IdType="pubmed">27070333</ArticleId></ArticleIdList></Reference><Reference><Citation>Polloni L., Muraro A. Anxiety and food allergy: A review of the last two decades. Clin. Exp. Allergy. 2020;50:420–441. doi: 10.1111/cea.13548.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cea.13548</ArticleId><ArticleId IdType="pubmed">31841239</ArticleId></ArticleIdList></Reference><Reference><Citation>Pajno G.B., Fernandez-Rivas M., Arasi S., Roberts G., Akdis C.A., Alvaro-Lozano M., Beyer K., Bindslev-Jensen C., Burks W., Ebisawa M., et al. EAACI guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy. 2018;73:799–815. doi: 10.1111/all.13319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.13319</ArticleId><ArticleId IdType="pubmed">29205393</ArticleId></ArticleIdList></Reference><Reference><Citation>Virkud Y.V., Burks A.W., Steele P.H., Edwards L.J., Berglund J.P., Jones S.M., Scurlock A.M., Perry T.T., Pesek R.D., Vickery B.P. Novel baseline predictors of adverse events during oral immunotherapy in children with peanut allergy. J. Allergy Clin. Immunol. 2017;139:882–888.e5. doi: 10.1016/j.jaci.2016.07.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2016.07.030</ArticleId><ArticleId IdType="pmc">PMC5337444</ArticleId><ArticleId IdType="pubmed">27609653</ArticleId></ArticleIdList></Reference><Reference><Citation>Muraro A., Tropeano A., Giovannini M. Allergen immunotherapy for food allergy: Evidence and outlook. Allergol. Sel. 2022;6:285. doi: 10.5414/ALX02319E.</Citation><ArticleIdList><ArticleId IdType="doi">10.5414/ALX02319E</ArticleId><ArticleId IdType="pmc">PMC9707367</ArticleId><ArticleId IdType="pubmed">36457723</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondoulet L., Dioszeghy V., Ligouis M., Dhelft V., Dupont C., Benhamou P. Benhamou. Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. Clin. Exp. Allergy. 2010;40:659–667. doi: 10.1111/j.1365-2222.2009.03430.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2222.2009.03430.x</ArticleId><ArticleId IdType="pubmed">20002446</ArticleId></ArticleIdList></Reference><Reference><Citation>Senti G., von Moos S., Kündig T.M. Kündig. Epicutaneous immunotherapy for aeroallergen and food allergy. Curr. Treat. Options Allergy. 2014;1:68–78. doi: 10.1007/s40521-013-0003-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40521-013-0003-8</ArticleId><ArticleId IdType="pmc">PMC4025904</ArticleId><ArticleId IdType="pubmed">24918342</ArticleId></ArticleIdList></Reference><Reference><Citation>Baroli B. Penetration of nanoparticles and nanomaterials in the skin: Fiction or reality? J. Pharm. Sci. 2010;99:21–50. doi: 10.1002/jps.21817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jps.21817</ArticleId><ArticleId IdType="pubmed">19670463</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong W.Y., Kwon M., Choi H.E., Kim K.S. Recent advances in transdermal drug delivery systems: A review. Biomater. Res. 2021;25:24. doi: 10.1186/s40824-021-00226-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40824-021-00226-6</ArticleId><ArticleId IdType="pmc">PMC8317283</ArticleId><ArticleId IdType="pubmed">34321111</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2012;46:3–26. doi: 10.1016/S0169-409X(00)00129-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0169-409X(00)00129-0</ArticleId><ArticleId IdType="pubmed">11259830</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaulagain B., Jain A., Tiwari A., Verma A., Jain S.K. Passive delivery of protein drugs through percutaneous route. Artif. Cells Nanomed. Biotechnol. 2018;46:472–487. doi: 10.1080/21691401.2018.1430695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21691401.2018.1430695</ArticleId><ArticleId IdType="pubmed">29378433</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones S.M., Agbotounou W.K., Fleischer D.M., Burks A.W., Pesek R.D., Harris M.W., Martin L., Thebault C., Ruban C., Benhamou P.H. Safety of epicutaneous immunotherapy for the treatment of peanut allergy: A phase 1 study using the Viaskin patch. J. Allergy Clin. Immunol. 2016;137:1258–1261.e10. doi: 10.1016/j.jaci.2016.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2016.01.008</ArticleId><ArticleId IdType="pubmed">26920463</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito S., Hirobe S., Kuwabara Y., Nagao M., Saito M., Quan Y.-S., Kamiyama F., Fujisawa T., Okada N. Immunogenicity of milk protein-containing hydrophilic gel patch for epicutaneous immunotherapy for milk allergy. Pharm. Res. 2020;37:35. doi: 10.1007/s11095-019-2728-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-019-2728-y</ArticleId><ArticleId IdType="pubmed">31950282</ArticleId></ArticleIdList></Reference><Reference><Citation>Rattanapak T., Birchall J., Young K., Ishii M., Meglinski I., Rades T., Hook S. Transcutaneous immunization using microneedles and cubosomes: Mechanistic investigations using optical coherence tomography and two-photon microscopy. J. Control. Release. 2013;172:894–903. doi: 10.1016/j.jconrel.2013.08.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2013.08.018</ArticleId><ArticleId IdType="pubmed">23978683</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss R., Hessenberger M., Kitzmüller S., Bach D., Weinberger E.E., Krautgartner W.D., Hauser-Kronberger C., Malissen B., Boehler C., Kalia Y.N., et al. Transcutaneous vaccination via laser microporation. J. Control. Release. 2012;162:391–399. doi: 10.1016/j.jconrel.2012.06.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2012.06.031</ArticleId><ArticleId IdType="pmc">PMC3462999</ArticleId><ArticleId IdType="pubmed">22750193</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheiblhofer S., Thalhamer J., Weiss R. Laser microporation of the skin: Prospects for painless application of protective and therapeutic vaccines. Expert. Opin. Drug Deliv. 2013;10:761–773. doi: 10.1517/17425247.2013.773970.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/17425247.2013.773970</ArticleId><ArticleId IdType="pmc">PMC3667678</ArticleId><ArticleId IdType="pubmed">23425032</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemiyeh P., Mohammadi-Samani S. Potential of nanoparticles as permeation enhancers and targeted delivery options for skin: Advantages and disadvantages. Drug Des. Dev. Ther. 2020;14:3271–3289. doi: 10.2147/DDDT.S264648.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S264648</ArticleId><ArticleId IdType="pmc">PMC7429187</ArticleId><ArticleId IdType="pubmed">32848366</ArticleId></ArticleIdList></Reference><Reference><Citation>Mönkäre J., Pontier M., van Kampen E.E.M., Du G., Leone M., Romeijn S., Nejadnik M.R., O’Mahony C., Slütter B., Jiskoot W., et al. Development of PLGA nanoparticle loaded dissolving microneedles and comparison with hollow microneedles in intradermal vaccine delivery. Eur. J. Pharm. Biopharm. 2018;129:111–121. doi: 10.1016/j.ejpb.2018.05.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpb.2018.05.031</ArticleId><ArticleId IdType="pubmed">29803720</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Zeng L., Song W., Liu J. Influencing factors and drug application of iontophoresis in percutaneous drug delivery: An overview of recent progress. Drug Deliv. Transl. Res. 2021;12:1–23.</Citation><ArticleIdList><ArticleId IdType="pubmed">33486687</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasi P. Poly (lactic acid)/poly (lactic-co-glycolic acid)-based microparticles: An overview. J. Pharm. Investig. 2019;49:337–346. doi: 10.1007/s40005-019-00453-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40005-019-00453-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi I., Hidaka Y., Oshizaka T., Takei C., Mori K., Sugibayashi K., Makino K. Chitosan-coated PLGA nanoparticles for transcutaneous immunization: Skin distribution in lysozyme-sensitized mice. Colloids Surf. B Biointerfaces. 2022;220:112916. doi: 10.1016/j.colsurfb.2022.112916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.colsurfb.2022.112916</ArticleId><ArticleId IdType="pubmed">36244133</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi I., Kagawa A., Makino K. Skin permeability and transdermal delivery route of 30-nm cyclosporin A-loaded nanoparticles using PLGA-PEG-PLGA triblock copolymer. Colloids Surf. A Physicochem. Eng. Asp. 2020;600:124866. doi: 10.1016/j.colsurfa.2020.124866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.colsurfa.2020.124866</ArticleId></ArticleIdList></Reference><Reference><Citation>Heine S., Aguilar-Pimentel A., Russkamp D., Alessandrini F., Gailus-Durner V., Fuchs H., Ollert M., Bredehorst R., Ohnmacht C., Zissle U.M. Thermosensitive PLGA–PEG–PLGA hydrogel as depot matrix for allergen-specific immunotherapy. Pharmaceutics. 2022;14:1527. doi: 10.3390/pharmaceutics14081527.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics14081527</ArticleId><ArticleId IdType="pmc">PMC9329805</ArticleId><ArticleId IdType="pubmed">35893787</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadlecová Z., Sevriugina V., Lysáková K., Rychetský M., Chamradová I., Vojtová L. Liposomes Affect Protein Release and Stability of ITA-Modified PLGA-PEG-PLGA Hydrogel Carriers for Controlled Drug Delivery. Biomacromolecules. 2023;25:67–76. doi: 10.1021/acs.biomac.3c00736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.biomac.3c00736</ArticleId><ArticleId IdType="pmc">PMC10777393</ArticleId><ArticleId IdType="pubmed">38135465</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J., Cui Y., Liu M., An Z., Li K., Gu X., Li P., Fan Y. Enhanced hydrophilicity of one-step electrosprayed red blood cell-like PLGA microparticles by block polymer PLGA-PEG-PLGA with excellent magnetic-luminescent bifunction and affinity to HUVECs. Eur. Polym. J. 2023;191:112040. doi: 10.1016/j.eurpolymj.2023.112040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eurpolymj.2023.112040</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomoda K., Yabuki N., Terada H., Makino K. Surfactant free preparation of PLGA nanoparticles: The combination of antisolvent diffusion with preferential solvation. Colloids Surf. A Physicochem. Eng. Asp. 2014;457:88–93. doi: 10.1016/j.colsurfa.2014.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.colsurfa.2014.05.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Fessi H., Puisieux F., Devissaguet J.P., Ammoury N., Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int. J. Pharm. 1989;55:R1–R4. doi: 10.1016/0378-5173(89)90281-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0378-5173(89)90281-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Baspinar Y., Borchert H.-H. Penetration and release studies of positively and negatively charged nanoemulsions—Is there a benefit of the positive charge? Int. J. Pharm. 2012;430:247–252. doi: 10.1016/j.ijpharm.2012.03.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2012.03.040</ArticleId><ArticleId IdType="pubmed">22486953</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoeller S., Sperger A., Valenta C. Lecithin based nanoemulsions: A comparative study of the influence of non-ionic surfactants and the cationic phytosphingosine on physicochemical behaviour and skin permeation. Int. J. Pharm. 2009;370:181–186. doi: 10.1016/j.ijpharm.2008.11.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2008.11.014</ArticleId><ArticleId IdType="pubmed">19073240</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao G., Zhang L., Bai S., Sun Y. Analysis of hydrophobic charge induction displacement chromatography by visualization with confocal laser scanning microscopy. Sep. Purif. Technol. 2011;82:138–147. doi: 10.1016/j.seppur.2011.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.seppur.2011.09.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkley M. A brief survey of methods for preparing protein conjugates with dyes, haptens, and crosslinking reagents. Bioconjugate Chem. 1992;3:2–13. doi: 10.1021/bc00013a001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bc00013a001</ArticleId><ArticleId IdType="pubmed">1616945</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi I., Suzuki T., Makino K. Iontophoretic transdermal delivery using chitosan-coated PLGA nanoparticles for transcutaneous immunization. Colloids Surf. A Physicochem. Eng. Asp. 2021;608:125607. doi: 10.1016/j.colsurfa.2020.125607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.colsurfa.2020.125607</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamoto T. Use of a new adhesive film for the preparation of multi-purpose fresh-frozen sections from hard tissues, whole-animals, insects and plants. Arch. Histol. Cytol. 2003;66:123–143. doi: 10.1679/aohc.66.123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1679/aohc.66.123</ArticleId><ArticleId IdType="pubmed">12846553</ArticleId></ArticleIdList></Reference><Reference><Citation>Takatani-Nakase T., Tokuyama E., Komai M., Takahashi K. Transcutaneous immunization system using a hydrotropic formulation induces a potent antigen-specific antibody response. PLoS ONE. 2012;7:e47980. doi: 10.1371/journal.pone.0047980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0047980</ArticleId><ArticleId IdType="pmc">PMC3480500</ArticleId><ArticleId IdType="pubmed">23110149</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu B., Lv X., Le Y. Chitosan-modified PLGA nanoparticles for control-released drug delivery. Polymers. 2019;11:304. doi: 10.3390/polym11020304.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/polym11020304</ArticleId><ArticleId IdType="pmc">PMC6419218</ArticleId><ArticleId IdType="pubmed">30960288</ArticleId></ArticleIdList></Reference><Reference><Citation>Pamujula S., Hazari S., Bolden G., Graves R.A., Chinta D.D., Dash S., Kishore V., Mandal T.K. Cellular delivery of PEGylated PLGA nanoparticles. J. Pharm. Pharmacol. 2012;64:61–67. doi: 10.1111/j.2042-7158.2011.01376.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2042-7158.2011.01376.x</ArticleId><ArticleId IdType="pmc">PMC3319145</ArticleId><ArticleId IdType="pubmed">22150673</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahoo S.K., Panyam J., Prabha S., Labhasetwar V. Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J. Control. Release. 2002;82:105–114. doi: 10.1016/S0168-3659(02)00127-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0168-3659(02)00127-X</ArticleId><ArticleId IdType="pubmed">12106981</ArticleId></ArticleIdList></Reference><Reference><Citation>Mares A.G., Pacassoni G., Marti J.S., Pujals S., Albertazzi L. Formulation of tunable size PLGA-PEG nanoparticles for drug delivery using microfluidic technology. PLoS ONE. 2021;16:e0251821. doi: 10.1371/journal.pone.0251821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0251821</ArticleId><ArticleId IdType="pmc">PMC8213178</ArticleId><ArticleId IdType="pubmed">34143792</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee M., Chanda N. Formulation of PLGA nano-carriers: Specialized modification for cancer therapeutic applications. Mater. Adv. 2022;3:837–858. doi: 10.1039/D1MA00600B.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D1MA00600B</ArticleId></ArticleIdList></Reference><Reference><Citation>Muraoka T., Adachi K., Ui M., Kawasaki S., Sadhukhan N., Obara H., Tochio H., Shirakawa M., Kinbara K. A structured monodisperse PEG for the effective suppression of protein aggregation. Angewandte chemie. 2013;52:2430–2434. doi: 10.1002/anie.201206563.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.201206563</ArticleId><ArticleId IdType="pubmed">23361965</ArticleId></ArticleIdList></Reference><Reference><Citation>Burton O.T., Tamayo J.M., Stranks A.J., Koleoglou K.J., Oettgen H.C. Allergen-specific IgG antibody signaling through FcγRIIb promotes food tolerance. J. Allergy Clin. Immunol. 2018;141:189–201. doi: 10.1016/j.jaci.2017.03.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2017.03.045</ArticleId><ArticleId IdType="pmc">PMC5671359</ArticleId><ArticleId IdType="pubmed">28479335</ArticleId></ArticleIdList></Reference><Reference><Citation>Oettgen H.C. Mast cells in food allergy: Inducing immediate reactions and shaping long-term immunity. J. Allergy Clin. Immunol. 2023;151:21–25. doi: 10.1016/j.jaci.2022.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2022.10.003</ArticleId><ArticleId IdType="pubmed">36328809</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt A., Mahé B., Costagliola D., Bonduelle O., Hadam S., Schaefer G., Schaefer H., Katlama C., Sterry W., Autran B., et al. Transcutaneous anti-influenza vaccination promotes both CD4 and CD8 T cell immune responses in humans. J. Immunol. 2008;180:1482–1489. doi: 10.4049/jimmunol.180.3.1482.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.180.3.1482</ArticleId><ArticleId IdType="pubmed">18209043</ArticleId></ArticleIdList></Reference><Reference><Citation>Rattanapak T., Birchall J.C., Young K., Kubo A., Fujimori S., Ishii M., Hook S. Dynamic visualization of dendritic cell-antigen interactions in the skin following transcutaneous immunization. PLoS ONE. 2014;9:e89503. doi: 10.1371/journal.pone.0089503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0089503</ArticleId><ArticleId IdType="pmc">PMC3933627</ArticleId><ArticleId IdType="pubmed">24586830</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen S.T., Nielsen G.D., Thygesen P. Investigation of the adjuvant effect of polyethylene glycol (PEG) 400 in BALB/c mice. Int. J. Pharm. 2002;231:51–55. doi: 10.1016/S0378-5173(01)00862-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0378-5173(01)00862-6</ArticleId><ArticleId IdType="pubmed">11719013</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>